With a double blind technique, emylcamate was compared with placebo and with meprobamate, a closely related compound, by a battery of psychologic tests which included sixteen. measurable variables. In single doses of 1,200 mg., meprobamate depressed performance where emylcamate did not; in doses of 1,800 mg., both drugs depressed performance. These comparisons do not, however, distinguish any
... [Show full abstract] difference in effect on anxiety.